Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
BridgeBio finds, develops, and delivers breakthrough medicines for genetic disease...
BridgeBio finds, develops, and delivers breakth...
OpGen, Inc. is a precision medicine company harnessing the power of molecular diag...
OpGen, Inc. is a precision medicine company har...
We are a pharmaceutical company currently in the preclinical stage, dedicated to d...
We are a pharmaceutical company currently in th...
Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering pres...
Founded in 1996, PetMed Express is America's La...
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...
CASI is a U.S. NASDAQ-listed biopharmaceutical ...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.